Gene: PLEKHG1
Official Full Name: pleckstrin homology and RhoGEF domain containing G1provided by HGNC
Gene Summary: Predicted to enable guanyl-nucleotide exchange factor activity and small GTPase binding activity. Predicted to be involved in regulation of small GTPase mediated signal transduction. Located in nucleoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO15059 | PLEKHG1 Knockout cell line (HeLa) | Human | PLEKHG1 | 1:3~1:6 | Negative | Online Inquiry |
KO15060 | PLEKHG1 Knockout cell line (HCT 116) | Human | PLEKHG1 | 1:2~1:4 | Negative | Online Inquiry |
KO15061 | PLEKHG1 Knockout cell line (HEK293) | Human | PLEKHG1 | 1:3~1:6 | Negative | Online Inquiry |
PLEKHG1 Gene Knockout Cell Lines are engineered cellular models that allow researchers to study the function and role of the PLEKHG1 gene in various biological processes. By utilizing CRISPR/Cas9 technology, these cell lines have had the PLEKHG1 gene selectively disrupted, resulting in a loss-of-function phenotype that facilitates an in-depth investigation into the molecular pathways influenced by this gene.
The key function of PLEKHG1 involves its role in regulating cellular signaling pathways, particularly those related to Rho family GTPases that govern actin cytoskeleton dynamics and cell morphology. The knockout cell lines provide a valuable tool for dissecting the downstream effects of PLEKHG1 and elucidating the complexities of intracellular signaling cascades. Researchers can observe alterations in cell movement, proliferation, and apoptosis in these modified lines compared to wild-type controls, thereby gaining insight into potential therapeutic targets for diseases linked to aberrant PLEKHG1 activity.
In clinical and research settings, the PLEKHG1 Gene Knockout Cell Lines serve vital roles in drug discovery, cancer research, and the study of developmental biology. These models can be instrumental in identifying novel interventions for diseases where PLEKHG1 has been implicated, such as cancer metastasis and neurodegenerative disorders, ultimately leading to improved patient outcomes.
What sets PLEKHG1 Gene Knockout Cell Lines apart from alternative models is their precision and reproducibility. Unlike traditional knockout methods that may have off-target effects, our CRISPR-engineered cell lines ensure a precise edit of the PLEKHG1 gene, resulting in reliable data that enhances the robustness of experimental findings. Additionally, these cell lines are readily available and compatible with a range of assays, making them accessible for various research applications.
For researchers and clinicians seeking to uncover the intricate roles of PLEKHG1, our product not only provides a high-quality model system but also represents a crucial resource in advancing scientific knowledge. With our commitment to delivering cutting-edge biological products and unwavering expertise in gene editing technologies, we empower the scientific community to explore new possibilities in genetic research and therapeutic development.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.